Targeting immune checkpoints such as PD-L1, TIM-3, or LAG-3 with ICIs in HCC can reverse the exhausted state of infiltrating T cells within the TME, thereby enabling them to exert their anti-tumor functions. Here, LAG3 is linked to hepatocellular carcinoma.